Characterization of an Anti-CD5 Directed CAR T-Cell against T-Cell Malignancies
-
Published:2020-02-01
Issue:2
Volume:16
Page:369-384
-
ISSN:2629-3269
-
Container-title:Stem Cell Reviews and Reports
-
language:en
-
Short-container-title:Stem Cell Rev and Rep
Author:
Wada Masayuki, Zhang Hongyu, Fang Liu, Feng Jia, Tse Charlotte Olivia, Zhang Wenli, Chen Qi, Sha Sha, Cao Yuanzhen, Chen Kevin H., Pinz Kevin G., Chen Xi, Fan Xing-Xing, Jiang Xun, Ma YupoORCID
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Firor, A. E., Jares, A., & Ma, Y. (2015). From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy. Experimental Biology and Medicine, 240(8), 1087–1098. 2. Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., et al. (2013). CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med, 5(177), 177ra138. 3. Arai, S., Meagher, R., Swearingen, M., Myint, H., Rich, E., Martinson, J., & Klingemann, H. (2008). Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: A phase I trial. Cytotherapy, 10(6), 625–632. 4. Maus, M. V., Grupp, S. A., Porter, D. L., & June, C. H. (2014). Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood, 123(17), 2625–2635. 5. Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., Mahnke, Y. D., Melenhorst, J. J., Rheingold, S. R., Shen, A., Teachey, D. T., Levine, B. L., June, C. H., Porter, D. L., & Grupp, S. A. (2014). Chimeric antigen receptor T cells for sustained remissions in leukemia. The New England Journal of Medicine, 371(16), 1507–1517.
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|